Synergestic effect of Atorvastatin and Fenofibrate in Doxorubicin Induced Cardio-Nephrotoxicity

Anthracyclines are among the most potent chemotherapeutic agent. Quinine- containing anthracycline antibiotic doxorubicin among the most potent chemotherapeutic agent. DOX causes an imbalance in the level of free oxygen radicals and antioxidants. The present study is designed to investigate the cardio and nephro protective effect of atorvastatin and fenofibrate in doxorubicin imduced cardiotoxicity and nephrotoxicityin rats. Atorvastatin is a member of the statin class of HMG-CoA reductase inhibitors and play a revolutionized role in the treatment of hypercholesterolemia. However, Fibrates are also used in therapy in many forms of hypercholesterolemia, usually in combination with statins. The result showed that Doxorubicin causes toxicity in heart and kidney along with liver. When treated with atorvastatin and fenofibrate then the level of CK-MB and LDH is decreased in heart and in kidney the level of Serum Cretinine and BUN is decreased. Atorvastatin and Fenofibrate significantly inhibit DOX-induced nephro-cardio oxidative stress as seen in the reduced level of Thio-barbituric acid Reactive substances (TBAR),SOD and GSH. In addition, there was significant changes confirmed by Histopathological studies. Hence, the present study confirms that atorvastatin and fenofibrate improve the cardiotoxic and nephrotoxic effect induced by doxorubicin through the regulation of oxidative stress response by HMG-CoA and PPAR-α pathway. The overall conclusion for the experimental study is Atorvastatin and Fenofibrate shows the protective role against Doxorubicin induced cardotoxicity and nephrotoxicity.